PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28057616-1	2017	The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test.	rucaparib	36-45	collagen type XI alpha 2 chain	Homo sapiens	21-25	
28588062-0	2017	Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.	rucaparib	114-123	collagen type XI alpha 2 chain	Homo sapiens	99-103	
34039959-0	2021	BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.	rucaparib	53-62	collagen type XI alpha 2 chain	Homo sapiens	38-42	
34039959-3	2021	Herein, we demonstrated that concurrent treatment with the PARP inhibitor rucaparib and the PI3K inhibitor BKM120 showed synergetic anticancer effects on GBM U251 and U87MG cells.	rucaparib	74-83	collagen type XI alpha 2 chain	Homo sapiens	59-63	
34030643-1	2021	BACKGROUND: ATLAS evaluated the efficacy and safety of the PARP inhibitor rucaparib in patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC).	rucaparib	74-83	collagen type XI alpha 2 chain	Homo sapiens	59-63	
32086346-0	2020	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.	rucaparib	79-88	collagen type XI alpha 2 chain	Homo sapiens	64-68	
32086346-8	2020	Conclusions: In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in ATM, CDK12, or CHEK2 However, patients with alterations in other DDR-associated genes (eg, PALB2) may benefit from PARP inhibition.	rucaparib	59-68	collagen type XI alpha 2 chain	Homo sapiens	126-130	
30940721-1	2019	In an interim analysis, the targeted PARP inhibitor rucaparib showed encouraging signs of disease control when used as a maintenance therapy for patients with platinum-sensitive advanced pancreatic cancer and a pathogenic mutation in BRCA1, BRCA2, or PALB2.	rucaparib	52-61	collagen type XI alpha 2 chain	Homo sapiens	37-41	
28264872-0	2017	A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.	rucaparib	46-55	collagen type XI alpha 2 chain	Homo sapiens	31-35	
28264872-1	2017	Purpose: Rucaparib is a potent, oral, small-molecule PARP inhibitor.	rucaparib	9-18	collagen type XI alpha 2 chain	Homo sapiens	53-57	
27702817-5	2017	Cytotoxicities of cisplatin and the PARP inhibitor rucaparib were assessed using sulforhodamine B (SRB) assays.	rucaparib	51-60	collagen type XI alpha 2 chain	Homo sapiens	36-40	
26438157-2	2015	The aim of this study was to evaluate the combination of the PARP inhibitor rucaparib with temozolomide and to correlate pharmacokinetic and pharmacodynamic studies with efficacy in patient-derived GBM xenograft models.	rucaparib	76-85	collagen type XI alpha 2 chain	Homo sapiens	61-65	
24632590-3	2014	Here, we demonstrate that three PARP drug candidates, namely, rucaparib, veliparib, and olaparib, have a clearly different in vitro affinity profile across a panel of diverse kinases selected using a computational approach that relates proteins by ligand similarity.	rucaparib	62-71	collagen type XI alpha 2 chain	Homo sapiens	32-36	
25558828-11	2014	Disruption of Rad51 foci formation, which compromises homologous recombination, was consistent with increased sensitivity of PCa cells to the PARP inhibitor Rucaparib.	rucaparib	157-166	collagen type XI alpha 2 chain	Homo sapiens	142-146